Association of glucagon-like peptide-1 receptor agonists with risk of gastrointestinal adverse events: evidence from a drug target Mendelian randomization

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are a novel class of medications promising for treating cardiovascular disease or obesity, while concerns regarding their potential gastrointestinal adverse events persist. In our study, we report that genetically proxied GLP-1RAs may increase risk of acute pancreatitis but not other gastrointestinal adverse events.